IPIX (Innovation Pharmaceuticals) Shiller PE Ratio: (As of Jul. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Innovation Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Innovation Pharmaceuticals  (OTCPK:IPIX) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Innovation Pharmaceuticals Shiller PE Ratio Related Terms


Innovation Pharmaceuticals Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for Innovation Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Innovation Pharmaceuticals Shiller PE Ratio Chart

Innovation Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Innovation Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

IPIX vs AXIM, RNAZ, APTX: Shiller PE Ratio Comparison

For the Biotechnology subindustry, Innovation Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Innovation Pharmaceuticals Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innovation Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Innovation Pharmaceuticals's Shiller PE Ratio falls into.



Innovation Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Innovation Pharmaceuticals's E10 for the quarter that ended in Sep. 2023 is calculated as:

For example, Innovation Pharmaceuticals's adjusted earnings per share data for the three months ended in Sep. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=-0.002/307.7890*307.7890
=-0.002

Current CPI (Sep. 2023) = 307.7890.

Innovation Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201312 -0.030 233.049 -0.040
201403 -0.020 236.293 -0.026
201406 -0.030 238.343 -0.039
201409 -0.040 238.031 -0.052
201412 -0.020 234.812 -0.026
201503 -0.020 236.119 -0.026
201506 -0.020 238.638 -0.026
201509 -0.020 237.945 -0.026
201512 -0.030 236.525 -0.039
201603 -0.030 238.132 -0.039
201606 -0.030 241.018 -0.038
201609 -0.020 241.428 -0.025
201612 -0.030 241.432 -0.038
201703 -0.030 243.801 -0.038
201706 -0.040 244.955 -0.050
201709 -0.030 246.819 -0.037
201712 -0.030 246.524 -0.037
201803 -0.020 249.554 -0.025
201806 -0.030 251.989 -0.037
201809 -0.010 252.439 -0.012
201812 -0.020 251.233 -0.025
201903 -0.010 254.202 -0.012
201906 -0.010 256.143 -0.012
201909 -0.010 256.759 -0.012
201912 -0.010 256.974 -0.012
202003 -0.004 258.115 -0.005
202006 -0.010 257.797 -0.012
202009 -0.003 260.280 -0.004
202012 -0.020 260.474 -0.024
202103 -0.010 264.877 -0.012
202106 -0.010 271.696 -0.011
202109 -0.005 274.310 -0.006
202112 -0.004 278.802 -0.004
202203 -0.003 287.504 -0.003
202206 0.000 296.311 0.000
202209 -0.003 296.808 -0.003
202212 -0.001 296.797 -0.001
202303 -0.001 301.836 -0.001
202306 -0.005 305.109 -0.005
202309 -0.002 307.789 -0.002

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Innovation Pharmaceuticals Business Description

Address 301 Edgewater Place, Suite 100, Wakefield, MA, USA, 01880
Innovation Pharmaceuticals Inc is a clinical-stage pharmaceutical company in the United States. It is engaged in developing therapies with oncology, dermatology, and antimicrobial applications. Its clinical trials focus on evaluating its drug candidates, including Kevetrin for the treatment of cancers; Brilacidin, a potential therapeutic for the treatment of the novel coronavirus. The company focuses on developing small molecule therapies to treat diseases in the areas of cancer, antibiotics, and inflammatory disease.